Prochymal for Acute Myocardial Infarction

Prochymal is currently being evaluated in clinical trials for the prevention of heart failure resulting from acute myocardial infarction, or heart attack. Prochymal has been demonstrated in animal models to prevent pathologic remodeling or scar formation in the area of the heart. Animal studies have demonstrated the ability of the product to return heart function to near normal levels in as few as 2 months.

Prochymal Preclinical Data

Untreated Control		Prochymal Treated

The circled region denotes the extent of the scar in each image. Left image: Dense scar formation and wall thinning is seen in control hearts. Right image: In contrast, the scar is limited and the ventricle wall remains thick in the hearts of MSC treated animals. These results demonstrate that MSC therapy limits heart wall thinning after myocardial infarction.

Prochymal Clinical Status

The Phase II trial is evaluating the safety and efficacy of Prochymal in conjunction with standard of care in patients following acute myocardial infarction. The clinical trial is a double-blind, placebo-controlled study being conducted at multiple sites with a target enrollment of 220 patients. Patients will be randomized to either Prochymal or placebo at a 1:1 ratio. Efficacy endpoints determined from cardiac MRI include end systolic volume, LVEF and the ability of Prochymal to preserve functional heart tissue, or limit scar formation following a heart attack.  In addition, functional and quality of life assessments will be performed. Patient enrollment is ongoing.

For more information about Prochymal for acute myocardial infarction, please see our clinical trial page or contact us for more information via e-mail at AMI@Osiris.com.